NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ensoma

Ensoma

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://ensoma.com/

Last Round

VC Round

Sep 22, 2025

Total Funding Raised

$255M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ensoma is a biotechnology company that develops in vivo genomic medicine to engineer blood and immune cells for disease treatment using innovative vectors for direct gene modification.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

in vivo gene therapygenomic medicinehematopoietic stem cell engineeringHSC engineeringoff-the-shelf gene therapyin vivo delivery platformgene editingvirus-like particleVLPcellular medicinebiotech drug developmentgenetic disease treatmentnext-gen gene therapyin vivo delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ensoma Comps

Public and private peers based on sector, stage, and business model.

Ensoma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ensoma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundSep 22, 2025
Series B ExtensionMay 16, 2023
Series BJan 5, 2023
Series AFeb 11, 2021

Key People

Founding team and executive leadership

Jim Burns

Chief Executive Officer

Executive Team

Ensoma Investors

Notable investors and investment history

Ensoma investors
InvestorRounds
SymBiosis Capital ManagementVC Round, Series B Extension, Series A, Series B
Mirae AssetVC Round, Series B
Bioluminescence VenturesSeries B, Series B Extension
Cormorant Asset ManagementVC Round, Series A, Series B
F-Prime CapitalSeries A, Series B
Arix BioscienceSeries B Extension, Series B
5AM VenturesVC Round, Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 3, 2025

    Presenting new preclinical data at the Society for Immunotherapy of Cancer Annual Meeting.

  • Sep 22, 2025

    $53M raised with participation from Qatar Investment Authority.

Ensoma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ensoma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ensoma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range51
Year Founded2019
Last FundingSep 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.